Effect of inflammatory bowel disease on clinical outcomes of hematopoietic cell transplantation for inborn errors of immunity [0.03%]
炎症性肠病对造血细胞移植治疗先天性免疫缺陷临床结局的影响
Ryu Yanagisawa,Satoshi Miyamoto,Yoji Sasahara et al.
Ryu Yanagisawa et al.
Background: Inflammatory bowel disease (IBD) is a phenotype of patients with inborn errors of immunity (IEI). Allogeneic hematopoietic cell transplantation (HCT) is an established curative treatment for IEI; however, the ...
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate E-Selectin Inhibition with Uproleselan to Reduce GI Toxicity During Autologous Hematopoietic Cell Transplantation for Multiple Myeloma [0.03%]
评估Uproleselan抑制E-选择素以降低自体造血细胞移植治疗多发性骨髓瘤期间胃肠道毒性的II期随机双盲安慰剂对照试验
Zachary D Crees,Keith Stockerl-Goldstein,Meaghan Ryan et al.
Zachary D Crees et al.
Kidney Function after Hematopoietic Cell Transplantation with Orca-T, Cyclophosphamide or Methotrexate GvHD Prophylaxis: a single-center retrospective study [0.03%]
以奥沙利铂、环磷酰胺或甲氨蝶呤作为移植物抗宿主病预防方案的造血干细胞移植后肾功能：一项单中心回顾性研究
Susan Ziolkowski,Alejandro Villar-Prados,Gomathy Parvathinathan et al.
Susan Ziolkowski et al.
Tailoring Intensity: A Perspective on Thiotepa, Busulfan and Fludarabine (TBF) Conditioning for Acute Leukemias and Myeloproliferative Neoplasms [0.03%]
个体化预处理方案强度——替莫唑胺、博舒替尼和氟达拉滨(TBF)方案在急性白血病和骨髓增殖性肿瘤中的应用思考
Zaid Abdel Rahman,Razan Mansour,Mohamad Kharfan-Dabaja et al.
Zaid Abdel Rahman et al.
Background: Optimal conditioning before allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains of paramount importance for outcomes in hematologic malignancies. Thiotepa-Busulfan-Fludarabine (TBF) is a che...
Immunogenicity and safety of third, fourth and subsequent COVID-19 vaccine doses in recipients of hematopoietic cell transplantation and cellular therapy [0.03%]
造血细胞移植和细胞治疗的新冠疫苗第三、第四及后续剂次接种者中的免疫原性和安全性
C Arianne Buchan,Gerard Agbayani,Katrina Hueniken et al.
C Arianne Buchan et al.
Background: Recipients of hematopoietic cell transplantation (HCT) and immune effector cellular (IEC) therapies are particularly vulnerable to infectious complications after treatment. Given the ongoing transmission of SA...
Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: BMT CTN 1702 Trial [0.03%]
基于供者检索预后的同种异体细胞移植的获取：BMT CTN 1702试验
Jason G Dehn,Brent Logan,Stephanie J Lee et al.
Jason G Dehn et al.
Background: Patients requiring allogeneic hematopoietic cell transplantation (HCT) have variable likelihoods of identifying an 8/8 HLA-matched unrelated donor (MUD). A Search Prognosis calculator can estimate the likeliho...
Pulmonary Complications Following Hematopoietic Cell Transplantation in Patients with Myelofibrosis: A Single-center Retrospective Cohort Analysis [0.03%]
造血干细胞移植后患者的肺部并发症：对原发性髓纤维化患者单中心回顾队列分析
Anne B Richardson,Kevin Ng,Ted A Gooley et al.
Anne B Richardson et al.
Background: Myelofibrosis (MF) is a clonal hematopoietic stem-cell disorder which frequently results in extramedullary hematopoiesis. Hematopoietic cell transplantation (HCT) is the only cure. While a two-fold increase in...
Exploration of In Vivo T-cell Depletion protocols in Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies [0.03%]
异基因造血干细胞移植治疗血液系统恶性肿瘤的供者T细胞去除方案探索研究
Hongru Chen,Yi Zhang,Yamin Fan et al.
Hongru Chen et al.
Graft-versus-host disease (GVHD) remains a major concern following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Two principal in vivo T-cell depletion (TCD) strategies-post-transplant cyclophosphamide (PTCY)-based and ant...
Personalized Desensitization for Donor-Specific Anti-HLA Antibodies in Allogeneic Blood or Marrow Transplantation [0.03%]
同种异体血液或骨髓移植中针对HLA特异性抗体的个性化脱敏疗法
Christian B Gocke,Marianna Zahurak,Ilias Sinanidis et al.
Christian B Gocke et al.
Background: Donor-specific anti-HLA antibodies (DSAs) are associated with increased graft failure in allogeneic blood or marrow transplantation (alloBMT). We previously demonstrated that a personalized desensitization str...
Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy Studies [0.03%]
未来一期CAR-T治疗研究界定剂量限制毒性（DLT）的推荐意见
Frederick L Locke,Sarah Nikiforow,Matthew J Frigault et al.
Frederick L Locke et al.
Chimeric antigen receptor T-cell (CAR T) therapies have demonstrated potential to provide long-term remission in incurable hematologic malignancies, and novel approaches for CAR T therapy continue to be developed for treating cancer and oth...